We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Prophotonix Limited | LSE:PPIX | London | Ordinary Share | COM SHS $0.001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.75 | 8.50 | 9.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
11/10/2019 08:26 | Buywell3. There is no axe to grind. I�m just making people aware of your devious and unsavoury tactics to dupe others for your own financial benefit. There are plenty of people who know you for who you are and the damage you try to do on other companies threads. You have obviously lost money yesterday and this is now an attempt at gaining some back. If you Slate other peoples investments then be prepared for the same treatment. | jamesrs1 | |
11/10/2019 08:25 | POST REMOVED | buywell3 | |
11/10/2019 08:24 | Nothing in the PR yesterday saying it�s a new customer. In fact is likely to be a current one if the have been working with them for four years. They need a capital raise. Turnover is likely to be less than 15m this year. But the main reason I�d never hold this, in the good years they just pay themselves more. Nothing in it for shareholders. | dr biotech | |
11/10/2019 08:13 | POST REMOVED | buywell3 | |
10/10/2019 13:14 | Buywell3 = lies and deception. Whenever you see his name. Also goes under the name of Buywell 1,2,3,. Investors beware. | jamesrs1 | |
10/10/2019 13:03 | Wonder how much new capital they�ll need? If they raise 1m at 0.5p anyone who holds is going to be ridiculously diluted. Seems the market has already seen through the pump. I expect a few more attempts at fluffing the share price before the placing. | dr biotech | |
10/10/2019 12:33 | Losik compensation 2018 $325K so cost of shares bought high by UK standards not such a hole in his earnings. | pugugly | |
10/10/2019 11:52 | POST REMOVED | buywell3 | |
10/10/2019 11:42 | POST REMOVED | buywell3 | |
10/10/2019 09:41 | Don�t believe somebody who is trying to make a quick buck by encouraging others to buy. It�s a clear ramp to the hilt then sell at a profit. | jamesrs1 | |
10/10/2019 09:24 | POST REMOVED | buywell3 | |
10/10/2019 09:22 | Buywell3 is openly slating this company on another thread advising others to take advantage of the rise before it returns to 1.5p. | jamesrs1 | |
10/10/2019 09:19 | POST REMOVED | buywell3 | |
10/10/2019 09:09 | Lots of red flags in that statement. Company hasn�t got enough cash to last five years - being a non regulatory RNS, smells of pump and dump to me. Your 12p ramp is down what 85% instead of 90? And then you think we�ve missed out. LOL | dr biotech | |
10/10/2019 09:00 | POST REMOVED | buywell3 | |
10/10/2019 08:59 | An extra $1m revenue per year you say? In the last H1 results they lost $1.6m of revenue in the last six months alone. | rcturner2 | |
10/10/2019 08:57 | Do I smell a ramp prior to a new placing????? | pugugly | |
10/10/2019 08:56 | POST REMOVED | buywell3 | |
10/10/2019 08:52 | POST REMOVED | buywell3 | |
10/10/2019 08:39 | Psml. �Missed the boat�. That particular boat being the titanic when Buywell was ramping this at 12p. Non binding agreement. Anyone else notice this was a PR announcement not an RNS. Can pretty much say what you like in those. | dr biotech | |
10/10/2019 08:25 | Shame you can't buys these shares unless you sign the US tax rules | amrishbhim | |
10/10/2019 08:10 | POST REMOVED | buywell3 | |
10/10/2019 08:01 | POST REMOVED | buywell3 | |
10/10/2019 08:00 | From recent results "As noted above, we are now forecasting revenues in the second half will broadly approximate those achieved in the first half. Whilst we expect to see the financial benefit of the cost savings initiatives enacted in the first half, the Board believes the Company will continue to be loss making and is committed to strengthening the Group's balance sheet. The Board is therefore reviewing all funding and strategic options available, both to ensure the short-term working capital needs of the Company continue to be met, as well as maximizing shareholder value over the longer term. | cottoner |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions